EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis

Hiroshi Nomoto iD, Sho Furusawa, Hiroki Yokoyama, Yuka Suzuki, Rimi Izumihara, Yuki Oe, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, Yoshio Kurihara und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae213 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Hiroshi Nomoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638,…. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Whether continuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) or switching to oral semaglutide is more beneficial for β-cell function is unclear.

Objective

To assess the efficacy of switching from DPP-4is to oral semaglutide for β-cell function compared with DPP-4i continuation.

Methods

Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted. Changes in markers for glucose metabolism, including homeostatic model assessment (HOMA2) scores and disposition index (DI), were compared between the groups.

Results

A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed. In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks. Regarding indices for β-cell function, changes in HOMA2-β as well as DI, reflecting the ability of β-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-β [P = .001] and +0.09 vs 0.0 in DI [P < .001]). Improvement in DI in the semaglutide group was correlated significantly to changes in body mass index (BMI), HbA1c, and fatty liver index reflecting liver steatosis. Multiple linear regression analysis revealed that dose of semaglutide (≥ 7 mg/day), reduction in fatty liver index, and metformin nonuse were independently associated with improvement of DI.

Conclusion

Switching to oral semaglutide ameliorated β-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and β-cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsDipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Glucagon-Like PeptidesDrug SubstitutionHypoglycemic AgentsHumansMaleFemaleMiddle AgedAdministration, OralAgedProspective StudiesBlood GlucoseInsulin ResistanceGlycated HemoglobinGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

dipeptidyl peptidase-4 inhibitorsemaglutidetype 2 diabetesβ-cell function

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like PeptidesBlood GlucoseHypoglycemic AgentsGlycated HemoglobinGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
  • Jiyugaoka Medical Clinic, Obihiro 080-0016, Japan.
  • Division of Diabetes and Endocrinology, Department of Medicine, Hakodate Central General Hospital, Hakodate 040-8585, Japan.
  • Sapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, Japan.
  • Kurihara Clinic, Sapporo 004-0053, Japan.

ORCID-Profile: Hiroshi Nomoto

Zitieren

APA

Nomoto, H., Furusawa, S., Yokoyama, H., Suzuki, Y., Izumihara, R., Oe, Y., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., Takeuchi, J., Kurihara, Y., Nakamura, A., & Atsumi, T. (2025). Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae213

Vancouver

Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, et al. Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae213

BibTeX
@article{Nomoto2025,
  author = {Nomoto, Hiroshi and Furusawa, Sho and Yokoyama, Hiroki and Suzuki, Yuka and Izumihara, Rimi and Oe, Yuki and Takahashi, Kiyohiko and Miya, Aika and Kameda, Hiraku and Cho, Kyu Yong and Takeuchi, Jun and Kurihara, Yoshio and Nakamura, Akinobu and Atsumi, Tatsuya},
  title = {Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae213}
}
Kostenlos starten →